title: Is adjuvant chemotherapy omissible in women with T1-2 stage, node-positive, luminal A type breast cancer?
abstract: OBJECTIVE
  The aim of this study was to evaluate whether hormonal breast cancer therapy without systemic chemotherapy is feasible in adjuvant settings in luminal A breast cancer.
  
  
  METHODS
  A database of 879 patients who underwent breast cancer surgery enrolled between January 2003 and December 2011 was reviewed. Patients with luminal A cancers were selected and grouped into those who received adjuvant hormonal therapy with (group C+) or without (group C - ) adjuvant systemic therapy.
  
  
  RESULTS
  In a multivariable analysis, axillary lymph node (ALN) metastasis was the only independent factor that revealed significantly different between the two groups in disease-free survival (DFS). The 5-year cumulative DFS was 82.3 versus 76.2% (P = 0.700) and overall survival (OS) was 83.9 versus 100% (P = 0.483) for C+ versus C -  breast cancer, respectively.
  
  
  CONCLUSIONS
  In our study, adjuvant chemotherapy in luminal A, T1-2N+ cancer showed no significant difference for DFS. We believe that the role of adjuvant chemotherapy for these women with hormonal therapy might have little benefit.
authors.forename: Hee Yong
authors.initials: HY
authors.lastname: Kwak
authors.forename: Byung Joo
authors.initials: BJ
authors.lastname: Chae
authors.forename: Yong Hwa
authors.initials: YH
authors.lastname: Eom
authors.forename: Young Ran
authors.initials: YR
authors.lastname: Hong
authors.forename: Jae Beom
authors.initials: JB
authors.lastname: Seo
authors.forename: Ja Seong
authors.initials: JS
authors.lastname: Bae
authors.forename: Sang Seol
authors.initials: SS
authors.lastname: Jung
authors.forename: Byung Joo
authors.initials: BJ
authors.lastname: Song
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
keywords: Breast,; Carcinoma,; Chemotherapy,; Survival